VIDEO: Adjuvant, neoadjuvant therapy in non-small cell lung cancer is ‘here to stay’
Click Here to Manage Email Alerts
Narjust Florez (Duma), MD, discusses results from two studies presented at World Conference on Lung Cancer — IMpower010 and NADIM-2
The interim analysis of the phase 3 data from IMpower010 focused on overall survival of patients with resected non-small cell lung cancer receiving atezolizumab (Tecentriq, Genentech) compared with best supportive care following chemotherapy, according to Florez, associate director of the Cancer Care Equity Program and thoracic medical oncologist at Lowe Center for Thoracic Oncology at Dana-Farber Cancer Institute.
“The data is still immature,” she said.
While IMpower010 evaluated adjuvant therapy, NADIM-2 investigated neoadjuvant therapy. NADIM-2, a phase 2 study, included patients with resectable clinical stage IIIa non-small cell lung cancer.
“One final take-home message from the NADIM-2 study is that all patients required histologic confirmation of lymph node involvement. So, patients need to be appropriately staged before they can go on the neoadjuvant regimen,” Florez said.
Before surgery, patients received either nivolumab (Opdivo, Bristol Myers Squibb) and paclitaxel plus carboplatin or paclitaxel plus carboplatin alone.
“Neoadjuvant therapy is here to stay,” she concluded.
References:
- Felip E, et al. Abstract PL03.09. Presented at: International Association for the Study of Lung Cancer World Conference on Lung Cancer (hybrid meeting); Aug. 6-9, 2022; Vienna.
- Provencio M, et al. Abstract PL03.12. Presented at: International Association for the Study of Lung Cancer World Conference on Lung Cancer (hybrid meeting); Aug. 6-9, 2022; Vienna.
Collapse
Healio Interviews
Click Here to Manage Email Alerts